We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0HB0 market cap is 4.77B. The company's latest EPS is USD -6.2995 and P/E is -5.16.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 117.91M | 203.2M | 41.41M | 14.24M | 26.82M |
| Operating Income | -426.33M | -316.15M | -387.83M | -389.05M | -391.49M |
| Net Income | -411.47M | -327.37M | 1.6B | -231.8M | -352.09M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 890.74M | 852.95M | 1.44B | 1.24B | 937.12M |
| Total Liabilities | 250.21M | 453.45M | 145.76M | 137.9M | 126.1M |
| Total Equity | 640.53M | 399.5M | 1.29B | 1.1B | 811.02M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -370.62M | -290.76M | -407.32M | -309.48M | -296.06M |
| Investing | 91.44M | 75.75M | 1.25B | 243.26M | 239.58M |
| Financing | 289.61M | 261.52M | -765.77M | 2.35M | 5.43M |
| Market Cap | 4.77B |
| Price to Earnings Ratio | -5.16 |
| Price to Sales Ratio | 67.74 |
| Price to Cash Ratio | 20.6 |
| Price to Book Ratio | 2.24 |
| Dividend Yield | - |
| Shares Outstanding | 55.89M |
| Average Volume (1 week) | 273 |
| Average Volume (1 Month) | 154 |
| 52 Week Change | 0.00% |
| 52 Week High | 85.29 |
| 52 Week Low | 85.29 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Agios Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.agios.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
